FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDaxor Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DXR
Daxor Corporation Stock AnalysisComprehensive stock analysis for Daxor Corporation (DXR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDXR
DXR
Daxor Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DXR
  1. Home
  2. Stocks
  3. Daxor Corporation

Daxor Corporation

🇺🇸DXR•NASDAQ

Daxor Corporation

🇺🇸DXR•NASDAQ
Market cap
$46.76M
P/E ratio
6.45

Your view on DXR

Mkt Cap
$46.76M
P/E
6.45
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Daxor Corporation

Industry
Medical - Instruments & Supplies
Sector
Healthcare
CEO
Michael Richard Feldschuh
Headquarters
109 Meco Lane, Oak Ridge, TN, US
Industry
Medical - Instruments & Supplies
Sector
Healthcare
CEO
Michael Richard Feldschuh
Headquarters
109 Meco Lane, Oak Ridge, TN, US
Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.

The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Daxor Corporation from FRC's valuation model, read against the market price. DXR last traded at $8.01, 6.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Daxor Corporation. Starting points for Daxor Corporation: P/E 6.4, EPS $1.25, beta 0.26 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Daxor Corporation. Trailing twelve-month EPS for Daxor Corporation stands at $1.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$23.00average of analysts' targets
Current price—

Buy

Targets, low to high

$23.00

Low $23.00

Middle $23.00

High $23.00

Analyst ratings

3 ratings
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterJun 2003Next quarterDec 2003This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.07−$0.04−$0.21−$0.03
Lowest estimate−$0.08−$0.05−$0.21−$0.03
Highest estimate−$0.06−$0.03−$0.21−$0.03
Number of analysts16711
A year ago——$1.841—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterJun 2003Next quarterDec 2003This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$900278.00$904183.00$9.30M$16.40M
Lowest estimate$720222.00$723346.00$9.30M$16.40M
Highest estimate$1.08M$1.09M$9.30M$16.40M
Number of analysts16711
A year ago——$503424.00—
Growth vs a year ago——+1747.3%—
Recent rating and target changes (5)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Daxor Corporation. Daxor Corporation has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DXR20 companies · 8 funds
Compare DXR with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACETAdicet Bio, Inc.HealthcareBiotechnology$23.4M
ADAGAdagene Inc.HealthcareBiotechnology$68.5M
BEATHeartBeam, Inc.HealthcareMedical - Specialties$21.6M
CRVOCervoMed Inc.HealthcareBiotechnology$21.9M
GANXGain Therapeutics, Inc.HealthcareBiotechnology$47.3M
GEGGreat Elm Group, Inc.Financial ServicesAsset Management$67.6M
LITSLite Strategy, Inc.HealthcareBiotechnology$24.1M
NEPHNephros, Inc.HealthcareMedical - Instruments & Supplies$31.4M
More Medical - Instruments & Supplies companies
TickerTypeCompanySectorExchangeMkt cap
WHSIWearable Health Solutions, Inc.HealthcareOTC$182,671
WSTWest Pharmaceutical Services, Inc.HealthcareNYSE$28.1B
XRAYDENTSPLY SIRONA Inc.HealthcareNASDAQ$1.7B
YBGJYubo International Biotech LimitedHealthcareOTC$1.2M
ZJYLJin Medical International Ltd.HealthcareNASDAQ$26.3M
SHWGYShandong Weigao Group Medical Polymer Company LimitedHealthcareOTC$3.0B
SMTISanara MedTech Inc.HealthcareNASDAQ$300.6M
SOAGYSartorius AGHealthcareOTC$82.3B
SOLVSolventum CorporationHealthcareNYSE$14.7B
SRTOYSartorius Stedim Biotech S.A.HealthcareOTC$209.8B
SSSGYSartorius AGHealthcareOTC$15.8B
STAASTAAR Surgical CompanyHealthcareNASDAQ$1.3B
ETFs holding Daxor Corporation
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets0.00%
VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%
VCNS.TOVanguard Conservative ETF Portfolio$977M in assets—
VRIF.TOVanguard Retirement Income ETF Portfolio$371M in assets—

Largest holders first, then the funds most concentrated in DXR.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Daxor Corporation, and how their positions are changing. At a $46.8M market value, institutional positions materially move Daxor Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Daxor Corporation executives and directors. Shares of Daxor Corporation have traded between $6.55 and $14.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Daxor Corporation. Coverage tracks Daxor Corporation within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Daxor Corporation.

DXR AnalysisGood
Past
1
Growth
5
Health
5
Profit
3
Value
4